Miao Yu

Miao Yu

Auto-generated profile, based on publicly available information

Miao Yu

Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MYMiao Yu
Miao Yu
GGGang Guo
Gang Guo
LHLei Huang
Lei Huang
LDLibin Deng
Libin Deng
CCChang-Sheng Chang
Chang-Sheng Chang
YCYan Cui
Yan Cui
CD73, an ecto-5′-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor. Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes. However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified. Here, we demonstrate that cancer-associated fibroblasts (CAFs) constitute the prominent CD73hi population in human colorectal cancers (CRCs) and two CD73− murine tumor models, including a modified CRC. Clinically, high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis. Mechanistically, CAF-CD73 expression is enhanced via an ADO-A2B receptor-mediated feedforward circuit triggered by tumor cell death, which enforces the CD73-checkpoint. Simultaneous inhibition of A2A and A2B pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors. Therefore, the strategic and effective targeting of both the A2B-mediated ADO-CAF-CD73 feedforward circuit and A2A-mediated immune suppression is crucial for improving therapeutic outcomes.

15 June 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
KFKendra Fick
Kendra Fick
YZYang Zhao
Yang Zhao
ZTZainab Tiamiyu
Zainab Tiamiyu
PCPatrick Czabala
Patrick Czabala
DPDakota B. Poschel
Dakota B. Poschel
KLKebin Liu
Kebin Liu
Despite the breakthrough in immune checkpoint inhibitor (ICI) immunotherapy in human cancer, colon cancer, except for the small subset of microsatellite instable human colon cancer, does not respond to ICI immunotherapy. As liver metastasis accounts for more than 90% of human colon cancer cases and mortality, ICI efficacy is primarily a measurement of liver metastasis suppression. Using a colon tumor liver metastasis syngeneic mouse model, we determined that mouse colon tumor liver metastases not only do not respond to anti–PD-1 immunotherapy but also exhibit no susceptibility to tumor-specific cytotoxic T lymphocyte (CTL) adoptive transfer immunotherapy. Analysis of human colon cancer liver metastases single-cell RNA sequencing (scRNA-seq) datasets revealed that histone methyltransferases of histone 3 lysine 9 trimethylation (H3K9me3) are upregulated in colon tumors and expressed in subsets of T cells in liver metastases of patients with human colon cancer. Targeted therapy with the H3K9me3-specific histone methyltransferase inhibitor F5446 suppresses colon tumor liver metastasis. scRNA-seq analysis revealed the accumulation of PD-1+Tim3+ exhausted T (Tex) cells in mouse colon tumor liver metastases, and F5446 treatment increased the level of IFNγhighPD-1low Tex cells. Furthermore, F5446 therapy increased IFNγhigh intermediate Tex (Tex-int) cells in human colon cancer patient liver metastases–derived xenografts (PDX) and suppressed PDX growth in humanized mice. In patients with human colon cancer, response to pembrolizumab is associated with tumor-infiltrating IFNγhigh Tex cells. Our findings determine that H3K9me3 promotes differentiation of Tex cells and targeting H3K9me3 is an effective approach to increase IFNγhigh Tex-int cells to reinvigorate CTL functionality to suppress colon cancer liver metastasis.




3 November 2026
Verified
Other
Open access
PDF file
KFKendra Fick
Kendra Fick
YZYang Zhao
Yang Zhao
ZTZainab Tiamiyu
Zainab Tiamiyu
PCPatrick Czabala
Patrick Czabala
DPDakota B. Poschel
Dakota B. Poschel
KLKebin Liu
Kebin Liu
Combined Supplementary figures and tables.